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Available online 2 January 2019Background: Invasive Pneumococcal Disease (IPD) is amajor public health concern. The effectiveness of 23-valent
polysaccharide pneumococcal vaccine (PPV23) against IPD in older age-groups is not fully understood.Wemea-
sured PPV23 effectiveness against IPD and interpreted changes in IPD incidence between 2000 and 2017.
Methods: Public Health England conducts enhanced national IPD surveillance in England andWales. The indirect
cohort method was used to estimate PPV23 effectiveness against IPD in individuals aged ≥65 years eligible for
PPV23 vaccination during 2012–2016. IPD incidence in 2016/17 was compared to rates during 2000–2003,
when neither PPV23 nor pneumococcal conjugate vaccines (PCVs) were routinely used in England and Wales.
Findings: PPV23 effectiveness, irrespective of time since vaccination, was 27% (95% CI, 17–35) after adjusting for
age, co-morbidity and year of infection. Vaccine effectiveness reduced non-significantly (p = 0.13) with time
since vaccination, from 41% (95% CI, 23–54) for those vaccinated within two years, to 34% (95% CI, 16–48) for
those vaccinated 2–4 years previously, and 23% (95% CI, 12–32) for those vaccinated ≥5 years previously. Vaccine
effectiveness did not vary significantly by age but was highest in previously healthy individuals (45%; 95%CI,
27–59). IPD incidence for PPV23 serotypes not included in the PCVs did not decrease after routine PPV23 use
but increased significantly since PCV introduction in 2006.
Interpretation: PPV23 offers moderate short-term protection against IPD in older adults. PPV23 serotypes com-
prise an increasing proportion of IPD cases in older adults because of serotype replacement following routine
PCV use in children.
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Trends1. Introduction available: the 23-valent pneumococcal polysaccharide vaccineStreptococcus pneumoniae is a major cause of morbidity and mortal-
ity worldwide, especially at the extremes of age and among those with
underlying comorbidities. Almost 100 pneumococcal serotypes have
been identified, based on their unique capsular polysaccharide struc-
ture. These serotypes each have different propensities for carriage and
invasive disease, including meningitis, septicaemia and pneumonia,
which can all be life-threatening. In order to prevent invasive pneumo-
coccal disease (IPD), two different types of vaccines are currentlyNational
, UK.
r the CC BY-NC(PPV23) and the pneumococcal conjugate vaccines (PCVs).
In the UK, prior to 2003, PPV23 had been available for more than
20 years and was recommended for individuals aged at least two
years with specific underlying clinical conditions that significantly in-
creased their risk of IPD [1]. Since 2003, a single dose of PPV23 was rec-
ommended for adults on their 65th birthday alongside a two-year
catch-up (2003–2005) for all ≥65 year-olds, starting with ≥80 year-
olds and moving to 75–79 and 65–74 year-olds by 2005. Currently,
around 70% of ≥65 year-olds have received a dose of PPV23, including
19% already vaccinated as part of the at-risk programme by 65 years
of age, 16% of new 65 year-olds and the remainder who receive the vac-
cine in subsequent years, usually before the age of 70 years [2].
In September 2006, the 7-valent PCV (PCV7)was introduced into the
infant immunisation programme alongside a 12-month catch-up for all-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in Context
Evidence Before This Study
We searched PubMed for “pneumococcal polysaccharide vac-
cine”, “PPV23”, “effectiveness”, “impact”, “trends”, “population”,
“Broome method” and “Indirect cohort method”. We searched for
population-based studies reported in the English language that in-
cluded adults aged 65 years and older, and compared trends in
vaccine-type and non-vaccine type invasive pneumococcal dis-
ease (IPD) before and after the start of the 23-valent pneumococ-
cal polysaccharide vaccine (PPV23) campaign, with no time
limits. A recent systematic review on PPV23 effectiveness in the
elderly identified 17 eligible studies and pooled vaccine effective-
ness against invasive pneumococcal disease by any serotype
was 73% (95%CI, 10–92%) in four clinical trials, 45% (95%CI,
15–65%) in three cohort studies, and 59% (95%CI, 35–74%) in
three case–control studies. The systematic review also found sig-
nificant effectiveness against pneumococcal pneumonia. In the
UK, our previous analysis during 1998/99 to 2009/10 found an
overall vaccine effectiveness of 24% which declined over time,
from 48% within 2 years of vaccination to 15% after 5 years.
At the population level, we did not observe any decline in IPD inci-
dence due to the PPV23 serotypes in the elderly following PPV23
implementation in the age group and prior to the implementation
of the childhood pneumococcal conjugate vaccine programmes.
Added Value of This Study
We followed up nearly 10,000 IPD cases in the elderly over a
4.5 year surveillance period (2012 to mid-2016). We found
PPV23 effectiveness, irrespective of time since vaccination, was
27% (95% CI, 17–35) after adjusting for age, co-morbidity and
year of infection,with non-significant waningwith time since vac-
cination, from 41% (95% CI, 23–54) for those vaccinated within
two years, to 34% (95% CI, 16–48) for those vaccinated
2–4 years previously, and 23% (95%CI, 12–32) for those vacci-
nated ≥5 years previously. Vaccine effectiveness by risk group
achieved borderline significance (p = 0.05) and was highest in
those without any risk factors (45%; 95% CI, 27–59) followed
by the high-risk immunocompetent (25%; 95% CI, 11–37) and
lowest in the immunocompromised (13%; 95% CI, −9 to 30).
There was no measurable impact of PPV23 on IPD incidence in
the elderly during 2000–2017. Following PCV7 and PCV13 imple-
mentation into the childhood immunisation programme, many of
the replacing serotypes subsequently causing IPD in the elderly
are currently included in PPV23 and not in PCV13, especially sero-
types 8, 9 N and 12F, which now constitute 40% of total IPD
cases in England and Wales.
Interpretation
PPV23 continues to demonstrate moderate short-term effec-
tiveness against IPD caused by the vaccine serotypes in older
adults, but this was insufficiently high to have an impact at the
population level following the campaigns in 2003–2005. The re-
cent increase in IPD due to some of the PPV23 serotypes in En-
gland and Wales would support continuation of the elderly
PPV23 programme, especially given the significant positive effec-
tiveness against the major replacing serotypes causing IPD in this
vulnerable age group. Extending the age at with PPV23 is offered
and/or offering additional PPV23 doses at regular intervals might
help prevent more cases of IPD.
43A. Djennad et al. / EClinicalMedicine 6 (2018) 42–50b2 year-olds. This programme led to a rapid and sustained decline in
PCV7-serotype IPD across all age groups through direct and indirect
(herd) protection [3]. The overall decline in IPD was, however, offset
by a small increase in IPD due to non-PCV7 serotypes across all age
groups because of serotype replacement in carriage and disease. In
April 2010, PCV7 was replaced with a 13-valent PCV (PCV13) without
a catch-up,which led to further declines in both PCV13-type and overall
IPD across all age groups although, again, with a small increase in re-
placement disease due to non-PCV13 serotypes [4].
Between 2003 and 2010, vaccine effectiveness (VE) of PPV23 using
the Broome method [5], was estimated to be 48% within two years of
vaccination, declining to 15% after five years [6]. Stratification by clinical
risk group and age suggested declining VE with age and lower vaccine
effectiveness in those with underlying co-morbidity, although these
were not statistically significant. In previously healthy 65–74 year-
olds, PPV23 VE was 65% (95% CI, 23–84) with 2 years of vaccination,
62% (95% CI, 21–82) from 2 to 5 years and 28% (95% CI,−72 to 70) be-
yond 5 years.
That study had been informative in deliberations by the United
Kingdom Joint Committee on Vaccines and Immunisation (JCVI) in
2013 and led to the decision to continue the elderly PPV23 programme.
The programmewas reviewed again in 2015 and the same decisionwas
made, with a plan to re-assess PPV23 impact and VE because of the rap-
idly changing epidemiology of IPD due to large declines in PCV13-
serotype IPD and replacement disease due to non-PCV13 serotypes as
a result of the childhood PCV13 programme [7]. This was undertaken
by Public Health England (PHE) in 2015, with additional resources
from theHorizon 20-20 IntegratedMonitoring of Vaccines Effectiveness
(I-MOVE+) network in Europe [8]. In this study, we report the popula-
tion impact and effectiveness of PPV23 on IPD among older adults in En-
gland and Wales over a 16-year period.
2. Methods
2.1. Vaccine Effectiveness Against IPD
PHE conducts enhanced national surveillance of IPD in England and
Wales, as described previously [4]. Laboratory-confirmed cases with
PPV23-type IPD (VT) and controls with non-PPV23 type IPD (NVT) are
identified through a combination of clinical and laboratory reporting.
National Health Service (NHS) hospital laboratories routinely submit in-
vasive pneumococcal isolates to PHE for confirmation and serotyping,
which is not performed locally. The laboratories also electronically re-
port clinically significant infections to PHE through the Second Genera-
tion Surveillance System (SGSS, previously LabBase2). Reports without
isolate submission are actively followed-up by PHE to ensure consis-
tently high serotyping rates for all invasive isolates across England and
Wales.
For this study, PHE asked general practitioners to complete a short
questionnaire on the clinical and immunisation history for all confirmed
IPD cases with known serotype among ≥65 years-olds, who were diag-
nosed between1 January 2012 and 30 June 2016. IPDwas defined as de-
tection of S. pneumoniae (culture, PCR or antigen) from a normally
sterile site. Final outcome (alive/dead) was ascertained by cross-
checking all cases with the Patient Demographics Service (PDS;
https://digital.nhs.uk/Demographics) in February 2017.
Based on the questionnaire returned by the GP underlying medical
conditions were categorised into three risk-groups as follows: none,
high-risk immunocompetent (chronic respiratory/heart/liver/renal dis-
ease; diabetes mellitus; cerebrospinal fluid leaks; cochlear implants)
and immunocompromised (asplenia/splenic dysfunction; malignancy;
or an immunosuppressive drug).
2.1.1. Statistical Methods for Effectiveness
Key variables (age, gender, period, clinical risk group, vaccina-
tion, ethnicity, clinical presentation, time registered at the GP,
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death within 30 days) were compared between cases and controls
using the chi-square test or Fisher's exact test as appropriate.
Vaccine effectiveness was calculated as 100% × (1 − the odds of
vaccination in VT cases / odds of vaccination in NVT controls) using
logistic regression to adjust for potential confounding factors of age
(65–69, 70–74, 75–79, 80–84 and ≥ 85 years), clinical risk group cat-
egory, gender, year of notification, and ethnicity. The influence of
these factors, which may be related to both vaccination and IPD,
was investigated by adding them sequentially in the order shown
above to the model. For missing values on a factor such as clinical
risk group, we used complete case analysis. This design method
which is a variant on a case–control design in which non vaccine
type cases serve as controls is known as the indirect cohort method
or Broome method5 and was originally developed for assessment of
PPV.
In the primary analysis for overall VE, vaccination was defined as
a PPV23 dose at any time prior to IPD. This was then assessed by time
since vaccination using a factor for vaccination with 4 levelsTable 1
Characteristics of cases and controls subject to age at disease, gender, period, underlying condi
manifestations General Practice registrations, and age at vaccination.
Variables Level
All data















Time since vaccination Unvaccinated
0 to b2 yrs
2 to b5 yrs
≥5 yrs
Yes & unknown time
Died in 30 days No
Yes
Missing
Intensive Care Unit Admission No
Yes
Missing













General Practice Registration b2 yrs
2 to b5 yrs
≥5 yrs
Missing




Yes & unknown time
⁎ p-Value comparing case and control distribution for each factor by chi-squared test or Fish(unvaccinated, vaccinated within b2 years, 2–4 years, ≥5 years). To
further investigate the long-term decline VE was also estimated
using a factor for each individual year from vaccination to IPD (up
to 16 years) and with a cubic spline and linear decline. Stratification
was also performed by age (65–74, 75–84, ≥85 years) and clinical
risk group (high risk immunocompetent, immunocompromised
and none). Differences across these strata were tested using the like-
lihood ratio test or Wald's test. VE against individual serotypes was
assessed by just including the controls and cases due to the individ-
ual serotype. Those vaccinated with unknown date were considered
in the analysis as vaccinated ever but dropped from the analyses in-
volving timing since vaccination.
Vaccine effectiveness against the different clinical manifestations
(meningitis, septicaemia and pneumonia), case fatality rate, ICU admis-
sion and hospital admission for ≥14 days were also estimated.
Sensitivity analyses were as follows: i) VE by age at vaccination
was considered rather than age at disease, ii) VE against vaccine-
related serotypes (i.e. those of the same serogroup rather than the
same serotype) by comparing these to the remaining controls, iii)tions, time since vaccination, 30 days mortality, ICU, hospital admission, ethnicity, clinical
Cases Controls Total p-Value⁎
4423 (71%) 1822 (29%) 6245
1827 (76%) 569 (24%) 2396 b0.0001
1576 (69%) 703 (31%) 2279
1020 (65%) 550 (35%) 1570
2386 (73%) 904 (27%) 3290 0.008
1990 (69%) 897 (31%) 2887
47 (69%) 21 (31%) 68
379 (77%) 112 (23%) 491 b0.0001
623 (65%) 333 (35%) 956
979 (68%) 471 (32%) 1450
1457 (71%) 602 (29%) 2059
985 (76%) 304 (24%) 1289
2275 (71%) 919 (29%) 3194 b0.0001
1164 (67%) 580 (33%) 1744
932 (75%) 303 (25%) 1235
52 (72%) 20 (28%) 72
1682 (76%) 534 (24%) 2216 b0.0001
194 (66%) 101 (34%) 295
260 (69%) 117 (31%) 377
2096 (68%) 972 (32%) 3068
191 (66%) 98 (34%) 289
3417 (71%) 1365 (29%) 4782 0.018
960 (68%) 446 (32%) 1406
46 (81%) 11 (19%) 57
2247 (72%) 887 (28%) 3134 b0.0001
518 (79%) 140 (21%) 658
1658 (68%) 795 (32%) 2453
2100 (74%) 755 (26%) 2855 b0.0001
847 (68%) 392 (32%) 1239
1476 (69%) 675 (31%) 2151
3922 (71%) 1576 (29%) 466
102 (69%) 46 (31%) 5498 0.004
34 (51%) 33 (49%) 148
47 (71%) 19 (29%) 67
318 (68%) 148 (32%) 66
3046 (73%) 1118 (27%) 4164 b0.0001
152 (63%) 90 (37%) 242
279 (65%) 150 (35%) 429
465 (66%) 242 (34%) 707
481 (68%) 222 (32%) 703
589 (66%) 305 (34%) 894 0.001
234 (75%) 79 (25%) 313
3090 (72%) 1220 (28%) 4310
510 (70%) 218 (30%) 728
1682 (76%) 534 (24%) 2216 b0.0001
637 (74%) 221 (26%) 858
1315 (69%) 597 (31%) 1912
598 (62%) 372 (38%) 970
191 (66%) 98 (34%) 289
er's exact test.
Fig. 1. Vaccine effectiveness by time since vaccination using the spline model and a linear
decline. Individual estimates for each year are also shown but are based on small numbers
within each year.
45A. Djennad et al. / EClinicalMedicine 6 (2018) 42–50only including records where the individual was registered at the GP
practice for ≥2 or ≥5 years at the date of IPD (on the assumption that
the patient's vaccination history was more likely to be accurate in
those registered at the same practice for longer).
2.2. Vaccine Impact Against IPD
National IPD data were analysed from the 2000/01 to 2016/17 ep-
idemiological years (from 01 July to 30 June the following year); the
study population comprised those aged ≥65 years (split across 5-
year age bands to ≥85 years) with IPD in England and Wales. Annual
incidence was calculated by dividing the number of corrected cases
by the population size for that age-group and year in England and
Wales. Corrected case numbers were calculated with adjustments
for missing age, serotype and underlying trends, and compared
using an over-dispersed Poisson model as described previously [4,
9]. This method assumes that the serotype distribution in those
with missing serotype is the same as in those with complete sero-
type. Also the age distribution in those with missing age is the
same as the age distribution where the age is known. In this model,
the inflation/deflation factors to correct for underlying trends in
total IPD prior to PCV introduction (which were applied until 2009/
10, after which it was assumed levels stabilised) were 3.82% for
65–69, 3.01% for 70–74, −1.08% for 75–79, 0.25% for 80–84,
−0.21% for 80+, and 0.99% for ≥65. So, for example, for 2004/05
(5 years before 2009/10), IPD was inflated by a factor of 1.03825 =
1.206. To assess impact to date, 2016/17 incidences were compared
to 2000/01–2002/03 (pre-routine PPV23) in the Poisson model. To
distinguish between PPV23 effects and PCV effects, serotypes were
grouped as PCV7, PCV13 only (in PCV13 but not PCV7), PPV23 only
(in PPV23 but not PCV13) and NVT (not in any vaccine).
2.3. Ethics Approval
PHE has legal permission, provided by Regulation 3 of The Health
Service (Control of Patient Information) Regulations 2002, to process
patient confidential information for national surveillance ofTable 2
Number of cases and controls by risk group, age group and time since vaccination as used in th
Time since vaccination Risk group Age
65–74
Cases Controls
























All 66 40communicable diseases (http://www.legislation.gov.uk/uksi/2002/
1438/regulation/3/made). This includes PHE's responsibility to mon-
itor the safety and effectiveness of vaccines.2.4. Role of the Funding Source
Invasive pneumococcal disease surveillance is internally funded
by Public Health England. The research is funded by a European Com-
mission project I-MOVE+ (Integrated Monitoring of Vaccines Effec-
tiveness in Europe) that received funding from the European Union's
Horizon 2020 research and innovation programme under grant
agreement #634446. The views expressed are those of the author
(s) and not necessarily those of the NHS, the NIHR, the Department
of Health or Public Health England.e vaccine effectiveness analyses.
75–84 85+ All
Cases Controls Cases Controls Cases Controls
233 87 191 86 779 248
97 47 65 32 355 162
112 36 97 27 515 114
5 3 11 3 33 10
447 173 364 148 1682 534
25 19 20 11 78 48
22 13 8 4 85 40
5 1 4 3 31 12
0 0 0 0 0 1
52 33 32 18 194 101
27 13 18 9 131 45
17 11 6 1 86 46
2 7 7 2 40 24
1 0 1 2 3 2
47 31 32 14 260 117
508 230 323 209 1173 540
282 150 112 66 586 286
142 49 118 70 322 140
8 2 4 2 15 6
940 431 557 347 2096 972
59 15 20 13 114 38
18 14 12 8 52 46
13 5 3 2 24 13
0 1 0 0 1 1
90 35 35 23 191 98
Table 3
Adjusted vaccine effectiveness of PPV23 (% with 95% confidence interval) stratified by age at IPD, risk group and time since vaccination.
Time since vaccination Risk Group Age at IPD
65–74 75–84 85+
VE% (95% CI) VE% (95% CI) VE% (95% CI)
0 to b2 years High risk immunocompetent 63 (30, 80) 53 (9, 75) 20 (−75, 64)
Immunocompromised 2 (−72, 44) 22 (−70, 64) −10 (−301, 70)
None 53 (−12, 80) −65 (−1434, 82) 60 (−92, 92)
Any risk 43 (17, 61) 38 (1, 62) 26 (−36, 60)
2 to b5 years High risk immunocompetent 21 (−35, 54) 20 (−63, 61) 3 (−127, 58)
Immunocompromised 20 (−32, 51) 30 (−64, 70) −174 (−2304, 69)
None 63 (26, 82) 91 (51, 98) 11 (−375, 83)
Any risk 35 (11, 53) 39 (0, 63) 6 (−81, 52)
≥5 years High risk immunocompetent 22 (−11, 44) 19 (−9, 40) 32 (7, 50)
Immunocompromised −8 (−59, 27) 12 (−32, 41) 14 (−46, 49)
None 48 (2, 73) 9 (−52, 45) 54 (22, 73)
Any risk 18 (−3, 36) 15 (−6, 31) 35 (18, 49)
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3.1. Vaccine Effectiveness Against IPD
3.1.1. Description of Cases and Controls
A total of 9847 IPD cases with serotyped isolates diagnosed in En-
gland andWales in older adults aged ≥65 years during 4.5 years of sur-
veillance (2012 to mid-2016) were followed-up and 6319 (64%)
returned the questionnaire. A higher response rate was obtained for
cases diagnosed during 2014–2016, when questionnaires were sent
closer to the time of IPD. Vaccination history was missing in 74 leaving
6245 cases for analysis; of these, 4423 (71%) were due to PPV23 sero-
types (cases) and 1822 (29%) were due to non-PPV23 serotypes (con-
trols) (Table 1). Healthy adults represented 20% (1235/6173), high-
risk immunocompetent individuals 52% (3194/6173) and immunocom-
promised individuals 28% (1744/6173) of cases and controlswhere clin-
ical risk group was known. Within the high-risk immunocompetent
group, the most commonly reported conditions were respiratory dis-
ease (52%), cardiovascular disease (50%), renal disease (32%) and diabe-
tes (30%) with other conditions reported for ≤5% of individuals. Within
the immunocompromised group,malignancy (84%)wasmost common.
The number of cases and controls stratified by age, risk and time since
vaccination are shown in Table 2.
3.1.2. Vaccine Effectiveness Overall, by Age Group, Risk Group and Time
Since Vaccination
Investigation of potential confounding factors showed that age-
group, risk-group and year of infection changed the estimate by only a
small amount (−4%, − 2%, +1%, respectively) while gender and eth-
nicity had no effect (b1%). Therefore, adjusted estimates are presented
with age-group, year of infection and risk-group adjustment. The overall
crude VE estimate was 32% (95% CI, 24–40) and adjusted VE was 27%Table 4
Overall adjusted vaccine effectiveness of PPV23 and estimates stratified by age at IPD, risk
group and time since vaccination.
Factor Level VE% (95% CI) p-Value⁎
All – 27 (17, 35)
Age at IPD 65–74 31 (16, 44) 0.85 (0.22)
75–84 17 (−3, 32)
85+ 34 (17, 47)
Risk group High risk immunocompetent 25 (11, 37) 0.050
Immunocompromised 13 (−9, 30)
None 45 (27, 59)
Time since vaccination 0 to b2 years 41 (23 to 54) 0.13 (0.23)
2 to b5 years 34 (16 to 48)
≥5 years 23 (12 to 32)
⁎ p-Value for difference in VE by strata and, in brackets the trend by age at IPD and time
since vaccination.(95% CI, 17–35). The VE estimates by time since vaccination, age and
risk group are summarised in Table 4; VE declined with time since vac-
cination, from 41% (95% CI, 23–54) for those vaccinated within two
years to 34% (95% CI, 16–48) for those vaccinated within 2–4 years
and 23% (95% CI, 12–32) for those vaccinated ≥5 years previously. Al-
though the overall linear declinewas not significant (p=0.13), the lon-
ger term decline was best fitted with the spline model which indicates
an initial drop from about 50% to a plateau after about 5 years at
20–25% (Fig. 1). The mean time since vaccination in this cohort was
quite long at 9.55 years.
When comparing VE between the three age-groups (Table 4), a
higher VE was observed for 65–74 year-olds (31%; 95% CI, 16–44) and
≥ 85 years old (34%; 95% CI, 17–35), but lower among 75–84 year-olds
(17%, 95% CI: −3 to 32). This difference by age groups was not signifi-
cant (p=0.85) norwas a trend in VE by age significant (p=0.22). Vac-
cine effectiveness by risk group achieved borderline significance (p =
0.05) and was highest in those without any risk factors (45%; 95% CI,
27–59) followed by the high-risk immunocompetent (25%; 95% CI,
11–37) and lowest in the immunocompromised (13%; 95% CI, −9 to
30).
VE differed significantly (p = 0.005) by vaccine serotype (Supple-
mentary Table 1) with no effectiveness seen for ST3 (2%; 95% CI, −21
to 21) and high VE for 9 N (50%; 95% CI, 37–61). Although there was
also low VE for ST 6B (−10%; 95%CI, −155 to 53) and 17F (2%, 95%CI,
−61 to 41) there was low precision for these serotypes. When ST3
was excluded from the analysis, there was no difference in VE across
the remaining serotypes (p= 0.13). VE across age-time-risk strata var-
ied from b0 to 90%, butwithwide confidence intervals (Table 3). For se-
rotypes with sufficient numbers of cases, there was not a significant
difference in waning by serotype. Within individual serotypes, too,
there was limited power to assess waning. For the three major sero-
types, VE (95% CI) at b2 years, 2–4 years and ≥ 5 years for serotype 8
was 53% (27–70%), 40% (12–59%) and 18% (−1–33%); for serotype
9 N, 69% (40–86%), 67% (41–82%) and 45% (29–58%); and for serotype
12F, 40% (−1–65%), 37 (−1–61%) and 24% (3–41%), respectively.
The current PPV23 programme for ≥65 year-olds focuses on the
healthy group who were not already eligible for the vaccine, based on
risk status. In this age group (65–74 year-olds), the VE was 54%, 65%
and 47% at b2, 2–4 and ≥ 5 years since vaccination. VE against IPD
cases that required intensive care admission was 34% (95% CI, 00–57)
and 19% (95% CI, 07–31) against hospital admission for ≥14 days; VE
was 25% (95% CI, −38 to 59) against meningitis, 29% (95% CI, 17–40)
against bacteraemic pneumonia and 28% (95% CI, −12 to 53) against
septicaemia, while VE against IPD death was 18% (95% CI, −5 to 36).
3.1.3. Sensitivity Analysis
Table 5 shows the overall adjusted VE of PPV23with vaccination sta-
tus also defined by the age at which vaccination occurred and interval
Table 5
Adjusted vaccine effectiveness of PPV23 by age at vaccination according to timing of vac-
cination relative to IPD.
Timing of vaccination relative
to IPD within those vaccinated
Age at vaccination if
vaccinated
VE% (95% CI) p-Value⁎
Any time before IPD b65 17 (−01, 31) 0.033
65–74 25 (13, 35)
75+ 35 (22, 46)
b5 years before IPD b65 54 (24, 71) 0.050
65–74 36 (17, 50)
75+ 30 (04, 48)
≥5 years before IPD b65 12 (−07, 28) 0.027
65–74 20 (07, 32)
75+ 35 (20, 47)
⁎ p-Value for difference in VE by age group.
47A. Djennad et al. / EClinicalMedicine 6 (2018) 42–50between vaccination and disease. The VE for vaccination among 65–74
year-olds (when most individuals received the vaccine) was 25% (95%
CI, 13–35), irrespective of the interval between vaccination and disease,
and 36% (95% CI, 17–50) for vaccination within the 5 years of IPD.
VE against vaccine-related serotypes (Table 6) was 4% (95% CI,−18
to 22), which justified including this group as part of the controls. Indi-
vidualswhowere registered at GP practices for ≥2 and ≥ 5 years, respec-
tively, at the time of diagnosis were used as a proxy for certainty of their
vaccination status. For the 4623 individuals registered for ≥2 years; the
adjusted VE, for vaccination at any time, was 39% (95%CI, 29–48), and
for the 4310 individuals registered for ≥5 years, the adjusted VE was
40% (95%CI, 30–49).
3.2. Vaccine Impact Against IPD
Between 2000/01 and 2016/17, there were 42,802 confirmed IPD
cases in older adults, including 7600 PCV7-type IPD, 8675 cases due to
the 6 additional PCV13 serotypes, 11,026 cases due to the 11 additional
PPV23 serotypes, 6253 non-PPV23 IPD cases and 9248 cases where the
serotype was not known. IPD incidence trends by age and serotype
group are summarised in Fig. 2, and the incidence rate ratios in
Table 7. In 2016/17, overall IPD incidence for ≥65 year-olds had dropped
by 15% compared to the pre-PPV23 period. While IPD incidence in-
creased sharply with age, the greatest proportional decline in overall
IPD incidence was in 65 to 69 year-olds. During this period, there was
a 96% decrease in PCV7-type IPD in all aged ≥65 years, 7% decrease in
cases due to the additional PCV13 serotypes and a 117% increase in
cases due to the additional PPV23 serotypes.
During 2003–2006, post-PPV23 campaigns and prior to PCV intro-
duction, Fig. 2 shows no clear evidence of an impact of these campaigns
on IPD, with varying trends in PPV23 only, PCV13 and PCV7 serotypes
(all of which are also in PPV23 except serotype 6A). Following PCV7
and PCV13 introduction in infants, herd effects led to large drops in
IPD due to the serotypes in these two vaccines, aswell as increases in se-
rotype replacement disease, both among non-vaccine serotypes and,Table 6
Adjusted vaccine effectiveness for vaccination at any time of PPV23 against
vaccine related serotypes, IPD clinical manifestations, IPD severity, and
against IPD when cases and controls are restricted to those registered at
their GP for at least 2, 5 years.
Any time and all ages VE% (95% CI)
Vaccine related serotypes 04 (−18, 22)
Meningitis 25 (−38, 59)
Pneumonia 29 (17, 40)
Septicaemia/Bacteraemia 28 (−12, 53)
ICU admission 34 (00, 57)
Hospital stay N14 days 19 (07, 31)
Mortality ≤30 days 18 (−05, 36)
Registered at GP ≥ 2 years 39 (29, 48)
Registered at GP ≥ 5 years 40 (30, 50)more recently, among the additional PPV23 serotypes. This means
that, despite the reduction in IPD cases due to PPV23 serotypes also
contained in PCV13, the additional PPV23 serotypes still form a large
proportion of all IPD among ≥65 year-olds in 2016/17. The recent in-
creases in replacement disease varied by age group, with overall IPD
rates increasing particularly steeply in ≥85 year olds.
4. Discussion
In England and Wales, PPV23 was 27% effective against the vaccine
serotypes causing IPD in older adults, irrespective of time since vaccina-
tion. This is a very important finding given the large changes in sero-
types causing IPD in older adults since the introduction of the
childhood pneumococcal conjugate vaccination programme more
than a decade ago. PPV23 effectiveness declined from 41% for those vac-
cinated within two years to 34% for those vaccinated within 2–4 years
and 23% for those vaccinated at least 5 years previously. Among ≥65
year-olds, vaccine effectiveness was higher in those who had no under-
lying medical conditions and in the younger age groups, although the
associations with age were not significant. PPV23 provided no measur-
able protection against vaccine-related serotypes. In 2016/17, overall
IPD incidence for ≥65 year-olds had dropped by 15% compared to the
pre-PPV23 period, almost entirely because of reductions in IPD cases
due to PCV7 and PCV13 serotypes that resulted from an indirect popu-
lation impact of the childhood PCV7 and PCV13 programmes,
respectively.
Our findings are similar to our previous analysis during 1998/99 to
2009/10, where we reported an overall VE of 24% which declined over
time, from 48% within 2 years of vaccination to 15% after 5 years [6].
At that time, too, the only impact on IPD incidence among ≥65 year-
olds was due to the childhood PCV7 immunisation programme, which
was introduced in 2006. Our estimates are lower than a recent
population-based case–control study of PPV23 VE against IPD among
people over 60 years in Spain, which reported an adjusted VE of 72%
(95% CI, 46–85) against overall IPD and 77% (95% CI, 40–92) against
vaccine-type IPD [11]. In a recent meta-analysis, too, significant VE for
PPV23 was reported against both IPD and pneumococcal pneumonia
in the elderly; the pooled VE against IPD was 73% (95% CI, 10–92) in
four clinical trials, 45% (95% CI, 15–65) in three cohort studies, and
59% (95% CI, 35–74) in three case–control studies [12]. It is likely that
the higher vaccine effectiveness in some of the studies, especially clini-
cal trials, may be due to a shorter follow-up periods compared to the
longer observational studies, where waning immunity is likely to ac-
count for the lower overall effectiveness.
An important difference when compared to our previous analysis
was the replacement of PCV7 with PCV13 in the childhood
immunisation programme in April 2010, without any catch-up. This
change resulted in a rapid and sustained decline in IPD due to the addi-
tional PCV13 serotypes, especially serotypes 7F and 19A, across all age
groups through the direct and indirect protection offered by the pro-
gramme. Consequently, overall IPD rates also declined during the first
4 years of the programme. Since 2013/14, however, this trend reversed,
with acceleration in replacement disease due some of the non-PCV13
serotypes, especially those included in PPV23 [9]. In particular, sero-
types 8, 9 N and 12F increased to such an extent – almost exclusively
in adults and older adults – that they are currently responsible for 40%
of all IPD in England and Wales [9]. It is, therefore, reassuring that
PPV23 has a significant VE against these major replacing serotypes al-
beit for a limited duration. Currently, more than half the IPD cases in
older adults are due to the additional PPV23 serotypes, making the
health economics for this vaccine even more favorable, even with its
limited individual-level effectiveness.
VE against serotypes that are common to both PPV23 and PCV13
show very wide confidence intervals because of relatively small num-
bers of cases. Notably, though, despite the successes of the childhood
PCV13 programme, IPD cases due to serotype 3 have continued to
Fig. 2. Corrected trends in the elderly IPD incidence in England and Wales from 2000/01 to 2016/17.
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type 19A are no longer declining and appear to be plateauing. The pro-
tection afforded by either PPV23 or PCV13 against serotype 3 IPD is
likely to be very limited, although it is reassuring that PPV23 has a pos-
itive VE against serotype 19A IPD [9].
Despite individual-level PPV23 effectiveness in older adults, there
was no clear impact at the population level of the routine use and
catch-up campaigns in the target population during 2003–2006
(Fig. 2). Thiswas assessed inmore detail previously [6], with the conclu-
sion that the expected impact based on incremental vaccine uptake and
moderate vaccine effectiveness was small and, therefore, it was not sur-
prising that no clear decreases were seen in IPD incidence. National sur-
veillance does indicate recent increases in non-PCV13 IPD rates,
especially among ≥85 year-olds, who had the highest disease incidence.As the population ages, these changeswill lead to increasing numbers of
IPD cases in the oldest populations. Given that VE remains positive in
the older age groups, this does raise the question as to PPV23 might
be more beneficial if given at an older age or if given at regular intervals
within the ≥65 year age-group. This would require additional analyses
[13,14].
We have previously reported the strengths and limitations of this
methodology [6]. A major strength remains the large numbers of con-
firmed IPD cases across all age groups identified through national sur-
veillance over a period of almost two decades, which has allowed us
to calculate VE with narrow confidence intervals, and stratify by age,
risk group and time. The use of non-PPV23 type IPD cases as controls
has the advantage of close matching in terms of underlying comorbidi-
ties, clinical characteristics, and other possible unmeasured
Table 7
Incidence rate ratios for all IPD, PCV7, PCV13 only, PPV23 only and non-PPV23 in 2016/17 versus average 2000–03 baseline by age.











65–69 All cases 534 (351) 21.20 397 (508) 15.77 0.74 0.64–0.87
PCV7 267 (89) 10.60 8 (10) 0.32 0.03 0.01–0.08
PCV13 only 90 (30) 3.58 78 (97) 3.10 0.87 0.58–1.32
PPV23 only 126 (42) 4.99 235 (292) 9.32 1.87 1.37–2.51
Non PPV23 51 (17) 2.03 76 (95) 3.03 1.49 0.93–2.50
70–74 All cases 590 (434) 27.29 483 (565) 22.33 0.82 0.71–0.94
PCV7 289 (107) 13.39 10 (11) 0.45 0.03 0.01–0.08
PCV13 only 104 (39) 4.84 81 (92) 3.76 0.78 0.52–1.15
PPV23 only 130 (48) 5.99 288 (326) 13.31 2.22 1.67–2.94
Non PPV23 66 (24) 3.07 104 (118) 4.82 1.57 1.03–2.41
75–79 All cases 516 (545) 29.30 489 (530) 27.78 0.95 0.82–1.09
PCV7 268 (137) 15.20 13 (14) 0.75 0.05 0.02–0.11
PCV13 only 93 (48) 5.28 94 (100) 5.35 1.01 0.70–1.47
PPV23 only 113 (58) 6.45 254 (269) 14.40 2.23 1.70–2.96
Non PPV23 42 (21) 2.37 128 (136) 7.28 3.07 2.01–4.75
80–84 All cases 591 (513) 45.43 471 (517) 36.23 0.80 0.69–0.92
PCV7 326 (130) 25.09 14 (15) 1.10 0.04 0.02–0.09
PCV13 only 99 (39) 7.59 80 (84) 6.15 0.81 0.54–1.22
PPV23 only 122 (49) 9.38 236 (248) 18.15 1.93 1.44–2.60
Non PPV23 44 (17) 3.36 141 (148) 10.83 3.22 2.05–5.12
≥85 All cases 846 (700) 70.06 786 (915) 65.11 0.93 0.83–1.04
PCV7 490 (194) 40.56 21 (24) 1.75 0.04 0.02–0.08
PCV13 only 149 (59) 12.32 167 (189) 13.81 1.12 0.83–1.50
PPV23 only 130 (51) 10.73 338 (383) 27.99 2.61 1.99–3.43
Non PPV23 78 (31) 6.45 260 (295) 21.56 3.34 2.38–4.67
≥65 All cases 3043 (2543) 34.01 2588 (3035) 28.93 0.85 0.80–0.90
PCV7 1624 (658) 18.15 65 (74) 0.73 0.04 0.03–0.06
PCV13 only 530 (215) 5.92 494 (562) 5.52 0.93 0.79–1.10
PPV23 only 614 (248) 6.86 1334 (1518) 14.91 2.17 1.92–2.47
Non PPV23 275 (111) 3.08 696 (792) 7.78 2.53 2.11–3.06
⁎ 95% confidence interval inflated from a Poisson interval based on over-dispersion of 2.1 seen from modelling 2000–03 pre-PCV7 all invasive pneumococcal disease data.
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only determined after the sample is submitted to the national reference
laboratory. A limitation that affects interpretation of the lower VE in
those with risk factors is that risk group status was reported at the
time of IPD and not at the time of vaccination. It is likely that many
will have developed risk factors after vaccination. Interpretation of the
age effects and decline in VE by time since vaccination also requires cau-
tion due to high case fatality rates in the oldest age groups,meaning that
thosewho survivemay be thosewho also had higher and better vaccine
responses. This is arguably not a bias but a feature of the population rep-
resented andwould generate thedecline to a plateau in VE by time since
vaccination and the increased VE in the oldest age group.
One potential limitation is that we only had 64% questionnaire re-
turn rate from GPs and this response rate was lower in 2012 and
2013, when questionnaires were sent 2–3 years after the case occurred;
also, questionnaires were less likely to be completed for fatal cases.
However, it is very unlikely that there was any bias within the com-
pleted questionnaires in terms of vaccination status or the serotype re-
sponsible for IPD. Another limitation is that the GPmay not know about
PPV23 vaccination status if the vaccine was given outside their surgery
or prior to the patient's enrolment to their surgery. This would misclas-
sify some vaccinated patients as unvaccinated and slightly underesti-
mate the VE. Another limitation is that some variables have a fairly
high proportion of missing values. A further limitation of the study is
that we only analysed invasive disease so VE estimates only apply to
IPD and not to the larger population who experience non-invasive
pneumococcal infections; although different studies have reported
mixed results, there is some evidence that PPV23 protects against
non-invasive pneumococcal infections, including non-bacteraemic
pneumococcal pneumonia [10].
PPV23 continues to demonstrate moderate short-term effectiveness
against IPD caused by the vaccine serotypes in older adults, but this wasinsufficiently high to have an impact on disease incidence at the popu-
lation level following the campaigns in 2003–2005. Significant declines
in IPD rates among older adults have been due to the indirect impact of
PCV7 followed by PCV13 introduction into the childhood immunisation
programme. The recent increase in IPD due to some of the additional
PPV23 serotypes in adults, especially serotypes 8, 12F and 9N, for
which significant VE were demonstrated with PPV23 is reassuring and
could make the PPV23 programme for older adults even more cost-
effective. Our findings should be generalisable to similar to other coun-
tries with established childhood PCV programmes and will help inform
modelling and cost-effectiveness studies to assess whether changing
the age at which PPV23 is offered and/or offering additional PPV23
doses to this vulnerable age group might help prevent more cases of
IPD.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.eclinm.2018.12.007.
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